PFIZER INC (PFE) Stock Price, Quote, News and Summary
NYSE:PFE - New York Stock Exchange, Inc. - US7170811035 - Common Stock
PFE Quote and Key Statistics
PFIZER INC
NYSE:PFE (1/17/2025, 10:28:26 PM)
Premarket: 26.39 +0.09 (+0.34%)26.3
-0.19 (-0.72%)
PFE Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.07% | ||
| ROA | 1.94% | ||
| ROE | 4.61% | ||
| Debt/Equity | 0.69 |
PFE Performance and Technical Analysis
PFE Ownership and Analysts
PFE Latest News and Analysis
What's going on in today's session: S&P500 most active stocks
Let's have a look at the most active S&P500 stocks in today's session.
Stay informed about the most active stocks in the S&P500 index on Monday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Let's have a look at the most active S&P500 stocks in today's session.
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Most active S&P500 stocks in Thursday's session
Tuesday's session: most active stock in the S&P500 index
These S&P500 stocks are the most active in today's session
3 Subtle Investing Mistakes I Won't Repeat in 2025 And Beyond
About PFE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 88,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK 10017 US
CEO: Albert Bourla
Employees: 88000
Company Website: https://www.pfizer.com/
Investor Relations: https://investors.pfizer.com
Phone: 12127332323
PFE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.77 | 349.49B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| SNY | SANOFI-ADR | 12.26 | 127.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.88 | 24.83B |